.After antibody-drug conjugate (ADC) specialist Seagen was actually sold to Pfizer in 2013 for a mas...
.On the heels of a phase 3 gain that neglected to impress investors, Ironwood Pharmaceuticals is act...
.Do not cease Monte Rosa Therapies right now. The Boston-based biotech is enjoying after authorizing...
.Welcome to this week's Chutes & Ladders, our roundup of notable leadership hirings, shootings an...
.Celebrating his company's upsized initial public offering (IPO), Septerna CEO Jeffrey Finer rang th...
.AbbVie has come back to the resource of its own antipsychotic goliath Vraylar trying to find anothe...
.GenSight Biologics is full weeks out of losing loan. Once again. The biotech just has enough cash t...
.Monopar Therapies is recouping a drug coming from the dump of AstraZeneca's uncommon ailment pipe. ...
.Along with new information out on Arcus Biosciences' experimental HIF-2a inhibitor, one group of an...
.After creating a genetics treatment collaboration along with Dyno Rehabs in 2020, Roche is back for...